Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding (2019 - 2025)

Historic Shares Outstanding for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $46.8 million.

  • 4D Molecular Therapeutics' Shares Outstanding fell 1004.96% to $46.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.8 million, marking a year-over-year decrease of 1004.96%. This contributed to the annual value of $45.8 million for FY2024, which is 631.16% up from last year.
  • 4D Molecular Therapeutics' Shares Outstanding amounted to $46.8 million in Q3 2025, which was down 1004.96% from $46.7 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Shares Outstanding's 5-year high stood at $52.0 million during Q3 2024, with a 5-year trough of $26.7 million in Q1 2021.
  • Its 5-year average for Shares Outstanding is $39.2 million, with a median of $42.0 million in 2023.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Shares Outstanding surged by 41875.17% in 2021 and then crashed by 1004.96% in 2025.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Shares Outstanding stood at $32.2 million in 2021, then increased by 1.25% to $32.6 million in 2022, then skyrocketed by 32.02% to $43.1 million in 2023, then rose by 6.31% to $45.8 million in 2024, then grew by 2.13% to $46.8 million in 2025.
  • Its Shares Outstanding was $46.8 million in Q3 2025, compared to $46.7 million in Q2 2025 and $46.3 million in Q1 2025.